(NASDAQ: EOLS) Evolus's forecast annual revenue growth rate of 21.88% is forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 4.28%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.94%.
Evolus's revenue in 2025 is $277,941,000.On average, 3 Wall Street analysts forecast EOLS's revenue for 2025 to be $19,329,296,906, with the lowest EOLS revenue forecast at $19,154,646,274, and the highest EOLS revenue forecast at $19,569,926,664. On average, 3 Wall Street analysts forecast EOLS's revenue for 2026 to be $24,858,800,578, with the lowest EOLS revenue forecast at $24,689,130,724, and the highest EOLS revenue forecast at $24,962,103,192.
In 2027, EOLS is forecast to generate $32,984,388,856 in revenue, with the lowest revenue forecast at $32,362,115,126 and the highest revenue forecast at $34,227,642,610.